Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-26 @ 12:18 PM
Ignite Modification Date:
2025-12-26 @ 12:18 PM
NCT ID:
NCT00006100
Eligibility Criteria:
DISEASE CHARACTERISTICS:
* Histologically proven Hodgkin's lymphoma
* Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation
* Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER)
* Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria:
* EBV seropositive
* HIV negative
* HTLV-1 negative
* Hepatitis B surface antigen and hepatitis B core antibody IgM negative
* Hepatitis C antibody negative
* Must share at least 1 HLA haplotype with donor
PATIENT CHARACTERISTICS:
Age:
* 18 to 75
Performance status:
* Not specified
Life expectancy:
* At least 8 weeks
Hematopoietic:
* Not specified
Hepatic:
* Bilirubin less than 2.0 mg/dL
* SGOT/SGPT less than 2.5 times normal (unless liver metastases are present)
* If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required
* No hepatic dysfunction causing moribundity
Renal:
* Creatinine clearance greater than 50 mL/min
* No renal dysfunction causing moribundity
Cardiovascular:
* No cardiac dysfunction causing moribundity
Pulmonary:
* No pulmonary dysfunction causing moribundity
Other:
* No neurologic dysfunction causing moribundity
* No history of severe transfusion reactions with blood products (including fetal calf serum)
* Not pregnant
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* See Disease Characteristics
Chemotherapy:
* See Disease Characteristics
* No concurrent antimetabolites
Endocrine therapy:
* Not specified
Radiotherapy:
* See Disease Characteristics
Surgery:
* Not specified
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
75 Years
Study:
NCT00006100
Study Brief:
Protocol Section:
NCT00006100